Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

被引:3
|
作者
Aparicio, Belen [1 ,2 ,3 ]
Ruiz, Marta [1 ,2 ,3 ]
Casares, Noelia [1 ,3 ]
Silva, Leyre [1 ,2 ,3 ]
Egea, Josune [1 ,2 ,3 ]
Perez, Patricia [4 ,5 ]
Albericio, Guillermo [4 ]
Esteban, Mariano [4 ]
Garcia-Arriaza, Juan [4 ,5 ]
Lasarte, Juan J. [1 ,3 ]
Sarobe, Pablo [1 ,2 ,3 ]
机构
[1] Univ Navarra, Ctr Invest Med Aplicada CIMA, Pamplona, Spain
[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Pamplona, Spain
[3] Inst Invest Sanitarias Navarra IdiSNA, Pamplona, Spain
[4] CSIC, Ctr Nacl Biotecnol CNB, Madrid, Spain
[5] Ctr Invest Biomed Red Enfermedades Infecciosas CI, Madrid, Spain
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 13卷
关键词
SARS-CoV-2; peptide vaccine; Omicron variant; cross-recognizing antibodies; conserved regions;
D O I
10.3389/fimmu.2022.1044025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Current vaccines against SARS-CoV-2, based on the original Wuhan sequence, induce antibodies with different degrees of cross-recognition of new viral variants of concern. Despite potent responses generated in vaccinated and infected individuals, the Omicron (B.1.1.529) variant causes breakthrough infections, facilitating viral transmission. We previously reported a vaccine based on a cyclic peptide containing the 446-488 S1 sequence (446-488cc) of the SARS-CoV-2 spike (S) protein from Wuhan isolate. To provide the best immunity against Omicron, here we compared Omicron-specific immunity induced by a Wuhan-based 446-488cc peptide, by a Wuhan-based recombinant receptor-binding domain (RBD) vaccine and by a new 446-488cc peptide vaccine based on the Omicron sequence. Antibodies induced by Wuhan peptide 446-488cc in three murine strains not only recognized the Wuhan and Omicron 446-488 peptides similarly, but also Wuhan and Omicron RBD protein variants. By contrast, antibodies induced by the Wuhan recombinant RBD vaccine showed a much poorer cross-reactivity for the Omicron RBD despite similar recognition of Wuhan and Omicron peptide variants. Finally, although the Omicron-based 446-488cc peptide vaccine was poorly immunogenic in mice due to the loss of T cell epitopes, co-immunization with Omicron peptide 446-488cc and exogenous T cell epitopes induced strong cross-reactive antibodies that neutralized Omicron SARS-CoV-2 virus. Since mutations occurring within this sequence do not alter T cell epitopes in humans, these results indicate the robust immunogenicity of 446-488cc-based peptide vaccines that induce antibodies with a high cross-recognition capacity against Omicron, and suggest that this sequence could be included in future vaccines targeting the Omicron variant.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies (vol 13, 1044025, 2023)
    Aparicio, Belen
    Ruiz, Marta
    Casares, Noelia
    Silva, Leyre
    Egea, Josune
    Perez, Patricia
    Albericio, Guillermo
    Esteban, Mariano
    Garcia-Arriaza, Juan
    Lasarte, Juan J.
    Sarobe, Pablo
    [J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [2] SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection
    Baerends, Eva A. M.
    Hvidt, Astrid K.
    Reekie, Joanne
    Sogaard, Ole S.
    Staerke, Nina B.
    Raben, Dorthe
    Nielsen, Henrik
    Petersen, Kristine T.
    Juhl, Maria R.
    Johansen, Isik S.
    Lindvig, Susan O.
    Madsen, Lone W.
    Wiese, Lothar
    Knudsen, Lene S.
    Iversen, Mette B.
    Benfield, Thomas
    Iversen, Kasper K.
    Andersen, Sidsel D.
    Juhl, Anna K.
    Dietz, Lisa L.
    Andreasen, Signe R.
    Fischer, Thea K.
    Erikstrup, Christian
    Valentiner-Branth, Palle
    Lundgren, Jens
    Ostergaard, Lars
    Tolstrup, Martin
    [J]. ISCIENCE, 2023, 26 (09)
  • [3] Waning natural and vaccine-induced immunity leading to reinfection with SARS-CoV-2 Omicron variant
    Shete, Anita M.
    Patil, Deepak Y.
    Sahay, Rima R.
    Sapkal, Gajanan N.
    Deshpande, Gururaj R.
    Yadav, Pragya D.
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [4] Vaccine-Induced SARS-CoV-2 Antibodies in Inflammatory Diseases
    Abbasi, Jennifer
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (14): : 1365 - 1365
  • [5] The SARS-CoV-2 Variant Omicron Is Able to Escape Vaccine-Induced Humoral Immune Responses, but Is Counteracted by Booster Vaccination
    Hastert, Florian D.
    Hein, Sascha
    von Rhein, Christine
    Benz, Nuka Ivalu
    Husria, Younes
    Oberle, Doris
    Maier, Thorsten J.
    Hildt, Eberhard
    Schnierle, Barbara S.
    [J]. VACCINES, 2022, 10 (05)
  • [6] COVID-19 vaccination induces humoral and cellular immunity to SARS-CoV-2 with cross-recognition of the Omicron variant and IgA secretion
    Ruhl, L.
    Kuehne, J. F.
    Beushausen, K.
    Keil, J.
    Christoph, S.
    Sauer, J.
    Falk, C. S.
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2022, 52 : 167 - 168
  • [7] Comparative Analysis of Vaccine-Induced Neutralizing Antibodies against the Alpha, Beta, Delta, and Omicron Variants of SARS-CoV-2
    Girl, Philipp
    von Buttlar, Heiner
    Mantel, Enrico
    Antwerpen, Markus H.
    Woelfel, Roman
    Mueller, Katharina
    [J]. VACCINES, 2024, 12 (05)
  • [8] SARS-CoV-2 vaccine-induced subacute thyroiditis
    Patel, Krupa R.
    Cunnane, Mary E.
    Deschler, Daniel G.
    [J]. AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2021, 43 (01)
  • [9] Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children
    Soto, Jorge A.
    Melo-Gonzalez, Felipe
    Gutierrez-Vera, Cristian
    Schultz, Barbara M.
    Berrios-Rojas, Roslye, V
    Rivera-Perez, Daniela
    Pina-Iturbe, Alejandro
    Hoppe-Elsholz, Guillermo
    Duarte, Luisa F.
    Vazquez, Yaneisi
    Moreno-Tapia, Daniela
    Rios, Mariana
    Palacios, Pablo A.
    Garcia-Betancourt, Richard
    Santibanez, Alvaro
    Pacheco, Gaspar A.
    Mendez, Constanza
    Andrade, Catalina A.
    Silva, Pedro H.
    Diethelm-Varela, Benjamin
    Astudillo, Patricio
    Calvo, Mario
    Cardenas, Antonio
    Gonzalez, Marcela
    Goldsack, Macarena
    Gutierrez, Valentina
    Potin, Marcela
    Schilling, Andrea
    Tapia, Lorena, I
    Twele, Loreto
    Villena, Rodolfo
    Grifoni, Alba
    Sette, Alessandro
    Weiskopf, Daniela
    Fasce, Rodrigo A.
    Fernandez, Jorge
    Mora, Judith
    Ramirez, Eugenio
    Gaete-Argel, Aracelly
    Acevedo, Monica L.
    Valiente-Echeverria, Fernando
    Soto-Rifo, Ricardo
    Retamal-Diaz, Angello
    Munoz-Jofre, Nathalia
    PedCoronaVac
    Meng, Xing
    Xin, Qianqian
    Alarcon-Bustamante, Eduardo
    Gonzalez-Aramundiz, Jose, V
    Le Corre, Nicole
    [J]. MBIO, 2022, 13 (06):
  • [10] Vaccine protection against the SARS-CoV-2 Omicron variant in macaques
    Chandrashekar, Abishek
    Yu, Jingyou
    McMahan, Katherine
    Jacob-Dolan, Catherine
    Liu, Jinyan
    He, Xuan
    Hope, David
    Anioke, Tochi
    Barrett, Julia
    Chung, Benjamin
    Hachmann, Nicole P.
    Lifton, Michelle
    Miller, Jessica
    Powers, Olivia
    Sciacca, Michaela
    Sellers, Daniel
    Siamatu, Mazuba
    Surve, Nehalee
    VanWyk, Haley
    Wan, Huahua
    Wu, Cindy
    Pessaint, Laurent
    Valentin, Daniel
    Van Ry, Alex
    Muench, Jeanne
    Boursiquot, Mona
    Cook, Anthony
    Velasco, Jason
    Teow, Elyse
    Boon, Adrianus C. M.
    Suthar, Mehul S.
    Jain, Neharika
    Martinot, Amanda J.
    Lewis, Mark G.
    Andersen, Hanne
    Barouch, Dan H.
    [J]. CELL, 2022, 185 (09) : 1549 - +